These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8250488)

  • 1. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin.
    Adcock WL; MacGregor A; Davies JR; Hattarki M; Anderson DA; Goss NH
    Biotechnol Appl Biochem; 1998 Oct; 28 ( Pt 2)():169-78. PubMed ID: 9756468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral validation of the manufacturing process of high purity albumin from placentas.
    Grandgeorge M; Véron JL
    Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures.
    Cameron R; Davies J; Adcock W; MacGregor A; Barford JP; Cossart Y; Harbour C
    Biologicals; 1997 Dec; 25(4):391-401. PubMed ID: 9467035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large scale use of Spherosil ion exchangers in plasma fractionation.
    Tayot JL; Tardy M; Gattel P; Cueille G; Liautaud J
    Dev Biol Stand; 1987; 67():15-24. PubMed ID: 3038636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
    Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
    Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of dengue virus in the plasma-derived therapeutic proteins.
    Xie YW; Chan PK; Szeto CK; Kwok SY; Chu IM; Chu SS; Cheung JL; Wong SW; Ali MB; Wong BL
    Transfusion; 2008 Jul; 48(7):1342-7. PubMed ID: 18315529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin.
    Adcock WL; MacGregor A; Davies JR; Hattarki M; Anderson DA; Goss NH
    Biotechnol Appl Biochem; 1998 Aug; 28(1):85-94. PubMed ID: 9693093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.